USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/2973
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBeţiu, Mircea
dc.contributor.authorBatîr, Irina
dc.contributor.authorCaisîm, Tatiana
dc.contributor.authorFiodorova, Nina
dc.contributor.authorEmeţ, Iulia
dc.date.accessioned2019-06-24T22:41:26Z
dc.date.available2019-06-24T22:41:26Z
dc.date.issued2016
dc.identifier.citationBEŢIU, Mircea, BATÎR, Irina, CAISÎM, Tatiana, et al. XeraCalm AD cremă in tratamentul adjuvant al dermatitei atopice = XeraCalm AD creme as adjuvant treatment in patients with atopic dermatitis. In: Curierul Medical. 2016, vol. 59, no 3, p. 23. ISSN 1875-0666.
dc.identifier.issn1857-0666
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/2973
dc.identifier.urihttp://moldmedjournal.md/wp-content/uploads/2016/09/Cm-3-PDF-1.pdf
dc.description.abstractObiectiv. Urmărirea eficienţei XeraCalm AD cremă în tratamentul complex al bolnavilor cu dermatită atopică (DA). Material şi metode. Lotul de studiu a cuprins 25 de pacienţi cu DA, cu vârste cuprinse între 2 şi 16 ani. La 15 pacienţi (lotul I) s-a constatat o formă uşoară de DA (media SCORAD – 10,5), ceilalţi 10 au constituit lotul II cu formă moderată de DA (media SCORAD – 25,4). Crema XeraCalm AD a fost aplicată de 2 ori în zi ca un adjuvant la terapia de bază (dermatocorticoizi şi antihistaminice), pe arii de xeroză cutanată pronunţată şi plăci cu aspect eritemato-scuamos. Durata tratamentului a constituit 2 săptămâni, urmat de un tratament anti-recidivă, aplicat de 2-3 ori pe săptămână, pe parcursul următoarelor 2 luni. Rezultate. La 14 (93,3%) pacienţi din lotul I, peste 5-7 zile s-a constatat dispariţia xerozei şi instalarea remisiunii clinice (efect foarte bun). La 6 (60%) bolnavi din lotul II, s-a stabilit involuţia eritemului şi păstrarea xerozei discrete la a 8 – a 10 zi, media SCORAD reducându-se de 2 ori (efect bun). Evoluţie stagnantă s-a raportat la 5 (20%) din totalul pacienţilor din lotul de studiu (efect insuficient). Recurenţele pe parcursul a 2 luni de tratament s-au observat în 7 (28%) cazuri. Concluzii. XeraCalm AD cremă este eficientă în tratamentul adjuvant de combatere a xerozei la atopici, facilitează reducerea indicelui SCORAD, având contribuţie anti-recidivă majoră în menţinerea remisiunii clinice.ro
dc.description.abstractObjectives. To follow up the efficacy of XeraCalm AD crème, a part of adjuvant complex treatment for patients with atopic dermatitis. Materials and methods. A total number of 25 patients with atopic dermatitis aged from 2 till 16 years were included in the research. In 15 patients (the 1st group) a mild form of atopic dermatitis was established (SCORAD mean – 10.5), another 10 (the 2nd group) presented a moderate form (SCORAD mean – 25.4). The XeraCalm AD crème was applied twice per day on sights with marked xerosis and erythematosquamous lesions as an adjuvant therapy for basic treatment (dermatocorticosteroids and antihistamines). Therapy lasted for 2 weeks, then antirecurrent treatment was made 2-3 times per week during the following 2 months. Results. In 14 (93.3%) patients from the 1st group, after 5-7 days of treatment, xerosis has disappeared completely and clinical remission occurred (a very good effect). In 6 (60%) patients from the 2nd group an erythema involution was observed, although a discrete xerosis was still present at 8-10 days of treatment, SCORAD mean decreased 2 times (a good effect). A stagnant evolution was reported in 5 (20%) out of all the number of patients included in the study (insufficient result). In 7 (28%) patients recurrence has developed during first 2 months of the treatment. Conclusions. XeraCalm AD crème is efficient adjuvant remedy for xerosis treatment in patients with atopic dermatitis, which facilitates decrease of SCORAD index, as well as represents a major antirecurrent effect.en
dc.publisherMinisterul Sănătăţii al Republicii Moldova, Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”en_US
dc.relation.ispartofCurierul Medical: Congresul V Naţional de Dermatologie cu participare internaţională, 9-11 iunie 2016, Chişinău, Republica Moldova
dc.subjectatopic dermatitisen_US
dc.subjecttreatmenten_US
dc.subjectXeraCalm AD crèmeen_US
dc.subject.meshDermatitis, Atopic--diagnosisen_US
dc.subject.meshDermatitis, Atopic--physiopathologyen_US
dc.subject.meshDermatitis, Atopic--drug therapyen_US
dc.subject.meshXeraCalm--therapeutic useen_US
dc.subject.meshOintments--therapeutic useen_US
dc.titleXeraCalm AD cremă în tratamentul adjuvant al dermatitei atopicero
dc.title.alternativeXeraCalm AD creme as adjuvant treatment in patients with atopic dermatitisen_US
dc.typeOtheren_US
Appears in Collections:Curierul Medical, 2016, Vol. 59, No 3

Files in This Item:
File Description SizeFormat 
XeraCalm_AD_crema_in_tratamentul_adjuvant_al_dermatitei_atopice.pdf70.06 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback